Fig. 3.
Vaccines with irradiated 12-AML cells induce systemic prophylactic and therapeutic immunity. (A) SJL mice (10 mice/ group) were vaccinated IV with irradiated 105 IL12-AML or control pac-AML cells and inoculated 1 week later with live 105 wt AML cells. Mice vaccinated with IL12-AML (•) cells develop antileukemia prophylactic immunity and are resistant to AML challenge, whereas control vaccinated mice (□) develop lethal leukemia. (B) Groups of SJL mice were injected IV with live 105 AML cells. On day 8 (•), 10 (▪), or 15 (▴) after AML inoculation, they were vaccinated IV with irradiated 105 IL12-AML cells. Control leukemic mice (□) did not receive vaccines. The day-8 vaccine experiment was performed twice with identical results.
